Nasdaq adds Moderna to Nasdaq-100 and lifts visibility for Moderna stock
Published on 10/06/2026 at 13:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Moderna Inc. (ISIN US60770K1079) was trading at EUR 180.20 at Lang & Schwarz on October 6, 2026 at 1:01 p.m. CEST, while Nasdaq prepares to add the biotechnology company to the Nasdaq-100. The inclusion is scheduled before market open on October 9, 2026, giving the stock a fresh index-related market event.
Nasdaq-100 inclusion starts October 9
According to Nasdaq on October 1, 2026, Moderna will become a Nasdaq-100 component before market open on October 9, replacing Warner Bros. Discovery. The change places Moderna in a benchmark tracked by index funds and increases the stock's visibility among large-cap technology and growth investors.
The index event comes after a sharp repricing in the US listing. Moderna's Nasdaq share price was last at USD 203.21 on October 5, 2026 at 4:00 p.m. EDT, against a 52-week range of USD 22.28 to USD 208.90, while market capitalization stood at USD 80.6 billion.
Revenue beat consensus in the second quarter
For the second quarter of 2026, Moderna reported revenue of USD 145.00 million and a GAAP net loss of USD 782.00 million. MarketBeat said the revenue figure exceeded the USD 102.93 million consensus forecast, while the adjusted loss of USD 1.97 per share was narrower than the USD 2.03 consensus loss.
The comparison shows why the index addition is only one part of the valuation debate. Moderna delivered a USD 42.07 million revenue beat against consensus in the second quarter, but the company remained loss-making, leaving pipeline execution central to the next phase of the investment case.
October data keeps the pipeline in view
Moderna's September 21, 2026 release said Phase 3 data for intismeran autogene in resected stage IIB-IV melanoma were selected for presentation at a Presidential Symposium. The company also scheduled an investor event for October 24, 2026, when the oncology program will receive a detailed data update, according to Moderna.
That date matters because the Nasdaq-100 inclusion arrives before a potentially important clinical disclosure. The company ended the second quarter with USD 1.7 billion in cash and cash equivalents, compared with USD 1.9 billion at the end of the first quarter, according to its reported quarterly figures.
Stock holds near its yearly high
At Lang & Schwarz, Moderna stock was trading at EUR 180.20 on October 6, 2026 at 1:01 p.m. CEST, down minus 0.27 percent versus the prior close of EUR 180.69. The neutral daily move leaves the Nasdaq-100 inclusion and the October 24 oncology event as the clearest dated reference points for the stock.
The further course of trading is shown by the continuously updated real-time quote of Moderna stock.
Moderna stock facts
- Company: Moderna, Inc.
- ISIN: US60770K1079
- Ticker: MRNA
- Primary exchange: NASDAQ
- Price Lang & Schwarz (as of October 6, 2026, 1:01 p.m. CEST): EUR 180.20
- Change versus prior close: minus 0.27 percent
- Prior close Lang & Schwarz (October 5, 2026): EUR 180.69
- Market capitalization: USD 80.6 billion (as of October 5, 2026)
- 52-week range: USD 22.28-208.90 (as of October 5, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Index membership: Nasdaq-100
